Abstract
A rapid, sensitive and selective liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for the identification and determination of olanzapine (OLZ, CAS 132539-06-1) in human plasma. Following liquid- liquid extraction, OLZ and loratadine (IS, CAS 79794-75-5) were separated using a mobile phase consisting of acetonitrile: aqueous ammonium acetate solution (pH 4.0, 10 mM) = 56:44 (v/v) on an Agilent ZORBAX Eclipse XDB-CN (2.1mmx150mm I.D., 5μm) column and analyzed by electrospray ionization mass spectrometry in the selected ion monitoring (SIM) mode using the respective [M+H]+ ions, m/z 313.15 for OLZ and m/z 383.00 for loratadine. The chromatographic separation was achieved in less than 6.0 min. The assay exhibited a linear dynamic range of 0.5–50 ng/ml for OLZ in human plasma and had good accuracy and precision. Both intra- and inter-batch standard deviations were less than 15%. The validated LC–MS method was first applied to a bioequivalence study in 20 healthy male Chinese volunteers.
Keywords: Application, Bioequivalence, Chinese volunteers, Determination, Identification, Human plasma, LC-MS, Loratadine, Olanzapine, Pharmacokinetics
Current Pharmaceutical Analysis
Title:Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study
Volume: 8 Issue: 3
Author(s): Jing Cao, Zunjian Zhang, Yuan Tian, Yuanyuan Li and Jianzhong Rui
Affiliation:
Keywords: Application, Bioequivalence, Chinese volunteers, Determination, Identification, Human plasma, LC-MS, Loratadine, Olanzapine, Pharmacokinetics
Abstract: A rapid, sensitive and selective liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for the identification and determination of olanzapine (OLZ, CAS 132539-06-1) in human plasma. Following liquid- liquid extraction, OLZ and loratadine (IS, CAS 79794-75-5) were separated using a mobile phase consisting of acetonitrile: aqueous ammonium acetate solution (pH 4.0, 10 mM) = 56:44 (v/v) on an Agilent ZORBAX Eclipse XDB-CN (2.1mmx150mm I.D., 5μm) column and analyzed by electrospray ionization mass spectrometry in the selected ion monitoring (SIM) mode using the respective [M+H]+ ions, m/z 313.15 for OLZ and m/z 383.00 for loratadine. The chromatographic separation was achieved in less than 6.0 min. The assay exhibited a linear dynamic range of 0.5–50 ng/ml for OLZ in human plasma and had good accuracy and precision. Both intra- and inter-batch standard deviations were less than 15%. The validated LC–MS method was first applied to a bioequivalence study in 20 healthy male Chinese volunteers.
Export Options
About this article
Cite this article as:
Cao Jing, Zhang Zunjian, Tian Yuan, Li Yuanyuan and Rui Jianzhong, Liquid Chromatography-Mass Spectrometry Method for the Determination of Olanzapine in Human Plasma and Application to a Bioequivalence Study, Current Pharmaceutical Analysis 2012; 8 (3) . https://dx.doi.org/10.2174/157341212801619351
DOI https://dx.doi.org/10.2174/157341212801619351 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Progress in Developing D3 Dopamine Receptor Ligands as Potential Therapeutic Agents for Neurological and Neuropsychiatric Disorders
Current Pharmaceutical Design Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology Cognitive Impairment and Dementia in Patients with Parkinson Disease
Current Topics in Medicinal Chemistry Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Adenosine in the Central Nervous System: Effects on Neurotransmission and Neuroprotection
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A2A Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Inflammatory Process in Parkinsons Disease: Role for Cytokines
Current Pharmaceutical Design Managing Sleep Disturbance in Bipolar Disorder
Current Psychiatry Reviews Recent Developments in Studies of l-Stepholidine and its Analogs: Chemistry, Pharmacology and Clinical Implications
Current Medicinal Chemistry Postoperative Delirium
Current Drug Targets Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy The Use of Bifunctional NOP/Mu and NOP Receptor Selective Compounds for the Treatment of Pain, Drug Abuse, and Psychiatric Disorders
Current Pharmaceutical Design Leukopenia Associated with Risperidone Treatment
Current Drug Safety A Review of Current Strategies for Treatment Resistant Obsessive-Compulsive Disorder
Current Drug Therapy Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Role of Dopamine Signaling in Drug Addiction
Current Topics in Medicinal Chemistry Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry